46 results about "HEART INFARCTION" patented technology

The present invention relates to a method for diagnosing myocardial infarction in a subject presenting with chest pain. The method is based on the determination of an amount of a cardiac troponin in a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample. Moreover, the present invention envisages a method for ruling in myocardial infarction and a method for ruling out myocardial infarction. The said methods are also based on the determination of the amount of a cardiac troponin in a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample.

The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

Systems and methods for delivering a device for regulating blood pressure between a patient's left atrium and right atrium are provided. The delivery apparatus may include a first catheter, a hub distal to the first catheter, the hub having one or more engagers disposed thereon, the one or more engagers configured to releasably engage with a first expandable end of the shunt in a contracted delivery state within a lumen of a sheath, and an second catheter extending through a center lumen of the first catheter and the hub, wherein the first catheter, the hub, and the second catheter are independently moveable relative to the sheath. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices may be used, for example, to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.

The present invention relates to a urea derivative of the formula (1)wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like]. In addition, it is useful as an agent for the prophylaxis or treatment of infectious diseases caused by bacteria or virus that invades via a C5a receptor.

The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP / PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

Ortho methoxy phenolic compounds are provided that include methylenedioxyphenyl ferulate and ferulylproline and derivatives thereof. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating cardiovascular diseases, including hypertension, atherosclerosis, coronary heart disease, angina, stroke, and myocardial infarction, are further provided. The compounds are also useful in reducing low-density lipoprotein oxidation, improving or increasing vasodilation, and reducing plaque destabilization in a subject.

The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (A) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.

The invention discloses a detection method in the technical field of biological engineering, in particular a method for diagnosing cardiac troponin I (cTn I) in a semi-quantitative mode by employing double-indicatrix immunochromatography. Acute myocardial infarction (AMI) is a serious disease in a coronary heart disease, is a common emergency among middle-aged and elderly people, and is high in death rate. According to statistics, one third to a half of patients die before being sent to a hospital. In the next 20 years, the AMI is a primary cause for death of the patients around the world. The cTn I is a reliable index which is currently acknowledged and has the highest specificity and the longest duration for myocardial infarction diagnosis. At present, cTn I detection methods which are commonly used in clinic comprise an enzyme-linked immunosorbent assay method and a radioimmunoassay method, which are time-saving, labor-saving, difficult to popularize and high in cost. An immune colloidal gold technology is quickly developed in recent years and can be widely applied to detection of communicable diseases, early pregnancy and cancers. By employing colloidal gold immunochromatography, a quick detection method for the cTn I is established. By adoption of the method, a cTn I gray area of 1 to 5 ng / ml can be subjected to semi-quantitative detection.

The invention discloses a pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and a preparation method thereof. The preparation comprises the following traditional Chinese medicinal components by weight: 6-15g of codonopsis pilosula, 6-15g of astragalus membranaceus, 6-15 parts of ligusticum wallichii, 8-15g of liquorice, 8-15g of pseudo-ginseng and 50-150ml of gingko leaf extract. The preparation method comprises the following steps: quenching the traditional Chinese medicinal materials for about 4 hours according to the requirement on dosage and quantity; uniformly stirring, adding the gingko leaf extract, and mixing; pouring the mixture in a traditional Chinese medicament extraction bag, putting the bag in a high-pressure kettle, and gradually heating to 105-115 DEG C; cooling to 100 DEG C in the high-pressure kettle, sealing and filling the liquid medicine into a finished product with 50-100ml in each bag to obtain the solution preparation; and storing at normal temperature. The pure plant traditional Chinese medicinal preparation can be used for improving micro-circulation of a human body, eliminating oxygen radicals, remarkably increasing the heart coronary blood flow, remarkably promoting brain blood circulation, increasing brain blood flow rate and regulating blood fat, so that the blood viscosity can be reduced, blood circulation can be improved, and the aging process of a human body can be delayed. The pure plant traditional Chinese medicinal preparation adopts pure plant traditional Chinese medicinal materials, is restrict in formula, mild in action, low in cost and small in dosage, gradually plays drug effects, and does hurt the liver or kidney of a patient.

VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and / or arteriogenesis, particularly in ischemic mammals, are disclosed.

The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

The invention relates to markers for acute myocardial infarction (AMI), particularly markers that may be used in the rapid and accurate diagnosis of AMI or reinfarction. A method of diagnosing cardiac injury comprising identifying an elevated concentration of cardiac myosin binding protein C (cMyBP-C) or a fragment thereof or myosin regulatory light chain 2 (MLC2) or a fragment thereof in a sample obtained from a subject.

The invention relates to a health product namely the Pushenkang health product. The health product is made from effective ingredients and an adjuvant which is acceptable in health products, wherein, the effective ingredients are made from the following bulk drugs by weight percentages: 26-40% of proanthocyanidin of grape seeds, 0.5-1.5% of resveratrol, 2-4% of ophidia black snake, 8-12% of rhodiola root, 8-12% of earth worm, 13-21% of ixeris sonchifolia, 7-11% of kudzuvine root and 13-21% of fruit of hawthorn. The formula combines the advanced international medical theory of resisting oxidation and clearing free radicals with the traditional formula of traditional Chinese medicine to protect organisms and histiocytes and prevent diseases from the source of body. The health product has the functions of preventing and treating coronary heart disease, angina pectoris and myocardial infarction, reducing blood sugar, resisting tumor, allergy, aging, enhancing immunity, beautifying and the like.

The invention relates to a Chinese patent medicament for treating heart disease, and in particular relates to channel dredging thrombolytic capsules for radically treating diseases such as coronary heart disease, angina and myocardial infarction and a making technology. The channel dredging thrombolytic capsules are formed by mixing the following components by weight: 0.03 to 0.1 gram of musk, 0.2 to 0.5 part of bezoar, 3 to 19 grams of ginseng, 9 to 30 grams of astragalus root, 5 to 10 grams of cordyceps sinensis, 10 to 30 grams of motherwort, 5 to 15 grams of Chinese angelica, and 3 to 10 grams of safflower. The making technology comprises the following steps of: grinding the musk and the bezoar into super micro powder, preparing coarse powder by extracting active ingredients from the ginseng, the astragalus root, the cordyceps sinensis, the motherwort, the Chinese angelica and the safflower, stirring the super micro powder and the coarse powder uniformly, and filling into capsules, thus obtaining the channel dredging thrombolytic capsules. The channel dredging thrombolytic capsules for treating coronary heart disease, angina and myocardial infarction in clinic have the advantages of extract curative effect, clear acting mechanism, toxic or side effect prevention and adverse response prevention.

The present disclosure involves the use of reprogramming factors including AKT1, GATA4, TBX5, MEF2C, HAND2 and either ZNF281 or AS-CL1 to reprogram adult non-cardiomyocytes, such as cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.

A traditional Chinese medicine for treating restenosis after myocardial infarction operation belongs to the traditional Chinese medicine field. The purpose of the invention is to provide a traditional Chinese medicine for treating restenosis after myocardial infarction operation, which is based on traditional Chinese medicine theory, primarily aims at activating blood and dissolving stasis, dredging veins, invigorating qi and warming yang, and secondarily aims at widening chest and benefiting diaphragm, eliminating vexation and dispelling melancholy. Raw materials for preparing effective components of the traditional Chinese medicine of the invention comprise, by weight: white peony roots, radix pseudostellariae, pseudo-ginseng, leeches, rhizoma sparganii, curcuma zedoary, trichosanthes kirilowii maxim, allium macrostemon, and haws. The traditional Chinese medicine of the invention is simple in preparation, low in price, good in curative effect, free of toxic or side effect, short in treatment period, and good in social and economic benefits. The traditional Chinese medicine of the invention is mainly used for treating coronary heart disease, myocardial ischemia, restenosis after myocardial infarction operation, and the like.

The invention discloses a one-step homogeneous-phase H-FABP oxygen channel chemiluminescence detection kit. The kit mainly comprises luminous microspheres resistant to H-FABP antibody coupling, photosensitive microspheres resistant to H-FABP antibody coupling, analysis and buffer liquid and a reaction hole. The invention further discloses a preparation method of the one-step homogeneous-phase H-FABP oxygen channel chemiluminescence detection kit. The method includes the steps of preparation of luminous microspheres resistant to H-FABP antibody coupling, preparation of photosensitive microspheres resistant to H-FABP antibody coupling and preparation of analysis and buffer liquid. Finally, the invention discloses a use method of the kit. The kit has the advantages of being high in sensitivity, good in specificity, broad in detection range, good in repeatability, easy to operate, free of cleaning and the like, it is convenient for the kit to be used for clinical detection, and the kit is used for monitoring the heart disease, can raise the accurate rate of diagnosis of myocardial infarction and has great market value.

The invention discloses a stasis-expelling blood-activating pain-relieving soup prepared by boiling the following raw materials in parts by weight and water: 30-40 parts of radix rehmanniae, 10-14 parts of fried peach kernels, 10-14 parts of red flower, 10-14 parts of angelica sinensis, 7-13 parts of ligusticum wallichii, 10-20 parts of root of common peony, 10-15 parts of radix bupleuri, 7-13 parts of liquorice, 12-15 parts of the root of bidentate achyranthes, 5-8 parts of pericarpium citri reticulatae, 7-13 parts of pericarpium citri reticulatae viride, 7-13 parts of grass hovenia dulcis, 12-18 parts of processed rhizoma cyperi and 10-14 parts of platycodon grandiflorum. By utilizing the stasis-expelling blood-activating pain-relieving soup, coronary heart disease, angina, myocardial infarction, heart disease, insufficient blood supply and myocardial ischemia caused by blood stasis qi stagnation and body ache caused by Bruce bacillus can be effectively treated, and the effects on diseases of chest distress, chest pain, palpitation, cardiopalmus, sweating, shortness of breath, gas compression, palpitation, fear, cowardice, troubled sleep, intermittent pulse, severe palpitation, and the like are obvious.

The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia / reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

The present invention relates to the use of elafin for the treatment and / or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodiment relates to a method and composition, using elafin, for protecting the heart muscle or other muscles from damage induced by abnormal blood flow and / or inflammation, which may result from, for example, a heart infarction. The present invention additionally or concomitantly relates to the use of elafin for the treatment and / or prevention of disorders or diseases which are associated with a rise in the level of troponin I and / or T.

The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia / reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

The invention belongs to the field of adult stem cells and regenerative medicine, and relates to the techniques of adult stem cell extraction, external expansion and differentiation induction as well as stem cell transplantation. The techniques are based on the theory that head and facial masticatory muscles have the same origin with cardiac progenitor cells. As shown by the analysis on the genetic expression, cardiac muscle genes Nk*2.5 and Isl1 in the masticatory muscle stem cells have expressions of different degrees. The techniques utilize that the masticatory muscle stem cells have the characteristics of the cardiac muscle stem cells, collect a masticatory muscle sample by the non-invasive biopsy method, and externally expands the masticatory muscle stem cells by the suspension culture method; and non-coding micro RNA (ribonucleic acid) is adopted to change the masticatory muscle stem cells and facilitate differentiation and purification of the masticatory muscle stem cells into the heart muscle cells. The transplantation of the purified cardiac muscle cells to a part with myocardial infarction is performed by means of the coronary artery duct injection or the cell membrane technique (the cell membrane is placed on the surface of myocardial infarction organization), so that the myocardial infarction or the ischemic heart disease can be cured.

The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

A therapeutic and / or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and / or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and / or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.

The present invention relates generally to assays, methods and kits for the prognosis and / or diagnosis of cardiac disorders. The present invention also provides, for example, binding agents to a novel class of circulating troponin biomarkers for use in predicting or diagnosing a cardiac disorder other than myocardial infarction or unstable angina. In addition, the binding agents of the present invention may be used to enhance the sensitivity and false positive performance of cardiac troponins in the prognosis and diagnosis of myocardial infarction.

The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6) alkoxy; and (C1-C6) haloalkoxy; for the preparation of a medicament for the prevention and / or treatment of diseases resulting from opening of the MPTP which are characterized by degenerative tissue damages, in particular, diabetes and diabetic complications, neurological diseases and stroke, heart infarction, inherited dystrophies and hepatitis, more particularly, diabetic vascular diseases, such as diabetic retinopathy, and neurodegenerative disorders, such as multiple sclerosis. Further objects are a group of selected individual compounds of formula (I) for use as medicaments and a further group of selected individual compounds of formula (I) as novel compounds.

The present invention relates to a preparation method of a spheroid using human-derived cardiac stem cells and a therapeutic use for ischemic heart disease using the myocardial regeneration effect thereof. The spheroid using the cardiac stem cells provided in the present invention has excellent myocardial differentiation ability and regenerative therapeutic ability as compared to existing cardiac stem cells, and thus may be used for the treatment of ischemic heart disease such as myocardial infarction.

The invention relates to an application of miRNA in treating cardiac hypertrophy. Particularly, the miRNA is hsa-miR-15a-5p / hsa-miR-16-5p, and the nucleotide sequences of the miRNA are shown as SEQ IDNO.1 and SEQ ID NO.2. The cardiac hypertrophy refers to a pathophysiological process which is caused by overloading of a heart due to genetic factors, hypertension, myocardial infarction, valve diseases and the like and mainly takes thickening of ventricular muscles and narrowing of ventricular cavities as main characteristics. The invention also relates to an application of a complex loaded withthe hsa-miR-15a-5p / hsa-miR-16-5p in preparing a medicament for treating cardiac hypertrophy, wherein the complex is a CHO-PGEA-nucleic acid complex.